Advanced search
Publication Cover
Expert Review of Anti-infective Therapy Volume 2, 2004 - Issue 3
Submit an article Journal homepage
117
Views
6
CrossRef citations to date
0
Altmetric
Review

Novel and re-emerging respiratory infections

Noel JC Snell Host Defence Unit, National Heart and Lung Institute, Dovehouse Street, Brompton, London SW3 6LY, UK. [email protected]
Pages 405-412 | Published online: 10 Jan 2014

References

  • Snell N. Examining unmet needs in infectious disease. Drug Discov. Today 8, 22–30 (2003).
  • Snell N. Bioterrorism today. Biologist 49(3), 140 (2002).
  • Duchin J, Koster F, Peters C, et al. Hantavirus pulmonary syndrome: a clinical description of 17 patients with a newly-recognized disease. N Engl. J. Med. 330, 949–955 (1994).
  • Bharadwaj M, Nofchissey R, Goade D, Koster F, Hjelle B. Humoral immune responses in the Hantavirus cardiopulmonary syndrome. J. Infect. Dis. 182, 43–48 (2000).
  • Peters C, Khan A. Hantavirus pulmonary syndrome: the new American haemorrhagic fever. Clin. Infect. Dis. 34, 1224–1231 (2002).
  • •Detailed review of the available knowledge of this condition.
  • Ferres M, Vial P. Hantavirus infection in children. Curr. Opin. Pediatr. 16, 70–75 (2004).
  • Hiiggins J, Hsiang C, Cosgriff T, et al Prospective, double-blind, concurrent, placebo-controlled trial of intravenous ribavirin therapy of haemorrhagic fever with renal syndrome. J. Infict Dis. 164, 1119–1127 (1991).
  • Chapman L, Mertz G, Peters C, et al Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Antiviral Ther 4, 211–219 (1999).
  • Hooper J, Larsen T, Custer D, et al A lethal disease model for hantavirus pulmonary syndrome. Virology 289, 6–14(2001).
  • Hjelle B. Vaccines against hantaviruses. Expert Rev. Vaccines 1(3), 373–384 (2002).
  • Murray K, Selleck P, Hooper P, et al A morbillivirus that caused fatal disease in horses and humans. Science 268, 94–97 (1995).
  • Young P, Halpin K, Selleck P, etal. Serologic evidence for the presence in Pteropus bats of a parvovirus related to equine morbillivirus. Emerg. Infect. Dis. 2, 239–240 (1996).
  • McCormack J, Allworth A, Selvey L, Selleck P. Transmissibility from horses to humans of a novel paramyxovirus, equine morbillivirus (EMV).J Infici. 38, 22–23 (1999).
  • Lam S, Chua K. Nipah virus encephalitis outbreak in Malaysia. Clin. Infect. Dis. 34\(Suppl. 2), S48—S51 (2002).
  • Chong H-T, Kamarulzaman A, Tan C-T, et al. Treatment of acute Nipah encephalitis with ribavirin. Ann. Neural 49, 810–813 (2001).
  • Guillaume V, Contamin H, Loth P, et al. Nipah virus: vaccination and passive protection studies in a hamster model. J. Viral 78, 834–840 (2004).
  • Nicholson K, Wood J, Zambon M. Influenza. Lancet 362, 1733–1745 (2003).
  • •Useful background review.
  • Chan P. Outbreak of avian influenza A (H5N1) virus infection in Hong Kong in 1997. Clin. Infect. Dis. 34\(Suppl. 2), S58—S64 (2002).
  • Peiris J, Yu W, Leung C, et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 363, 617–619 (2004).
  • Tran TH, Nguyen TL, Nguyen TD, et al Avian influenza A (H5N1) in ten patients in Vietnam. N Engl J. Med. 350, 1179–1188 (2004).
  • Koopman M, Wilbrink B, Conyn M. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in The Netherlands. Lancet 363, 587–593 (2004).
  • Palese P, Basler C, Garcia-Sastre A. The makings of a killer. Nature Med. 8, 927–928 (2002).
  • Barclay W, Zambon M. Pandemic risks from bird flu. Br. Med. J. 328, 238–239 (2004).
  • Webby R, Perez D, Coleman J, et al. Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. Lancet 363, 1099–1103 (2004).
  • Van den Hoogen B, de Jong J, Groen J, et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nature Med. 7, 719–724 (2001).
  • •The initial report on this newly recognized pathogen.
  • Peret T, Boivin G, Li Y, et al. Characterisation of human metapneumoviruses isolated from patients in North America. J. Infect. Dis. 185, 1660–1663 (2002).
  • Cuevas L, Nasser A, Dove W, Gurgel R, Greensill J, Hart C. Human metapneumovirus and respiratory syncytial virus, Brazil. Emerg. Infect. Dis. 9, 1626–1628 (2003).
  • Madhi S, Ludewick H, Abed Y, Klugman K, Boivin G. Human metapneumovirus-associated lower respiratory tract infections among hospitalized human immunodeficiency virus Type 1 (HIV-1)-infected and HIV-1-uninfected African infants. Clin. Infect. Dis. 37, 1705–1710 (2003).
  • Wolf D, Zakay-Rones Z, Fadeela A, Greenberg D, Dagan R. High seroprevalence of human metapneumovirus among young children in Israel. J. Infect. Dis. 188, 1865–1867 (2003).
  • Nissen M, Siebert D, MacKay I, Sloots T, Withers S. Evidence of human metapneumovirus in Australian children. Med. J. Aust. 176, 188 (2002).
  • Ebihara T, Endo R, Kikuta H, Ishiguro N, Ishiko H, Kobayashi K. Comparison of the seroprevalence of human metapneumovirus and human respiratory syncytial virus. J. Med. Virol. 72, 304–306 (2004).
  • Williams J, Harris P, Tollefson S, et al. Human metapneumovirus and lower respiratory tract disease in otherwise healthy children. N Engl. J. Med. 350, 443–450 (2004).
  • Stockton J, Stephenson I, Fleming D, Zambon M. Human metapneumovirus as a cause of community-acquired respiratory illness. Emerg. Infect. Dis. 8, 897–901 (2002).
  • Mullins J, Erdman D, Weinberg G, et al Human metapneumovirus infection among children hospitalized with acute respiratory illness. Emerg. Infict Dis. 10, 700–705 (2004).
  • McIntosh K, McAdam A. Human metapneumovirus — an important new respiratory virus. N Engl J Med. 350, 431–433 (2004).
  • •Detailed review of current knowledge of human metapneumovirus.
  • Stadler K, Masignani V, Eickmann M, et al SARS — beginning to understand a new virus. Nature Rev. Microbial 1, 209–218 (2003).
  • Peiris J, Lai S, Poon L, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361, 1319–1325 (2003).
  • Kuiken T, Fouchier R, Schutten M, et al Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 362, 263–270 (2003).
  • Pene F, Merlat A, Vabret A, et al Coronavirus 229E-related pneumonia in immunocompromised patients. Clin. Infict. Dis. 37, 929–932 (2003).
  • Holmes K. SARS coronavirus: a new challenge for prevention and therapy. J. Clin. Invest. 111, 1605–1609 (2003).
  • Peiris J, Yuen K, Osterhaus A, Stohr K. The severe acute respiratory syndrome. N Engl J. Med. 349, 2431–2441 (2003).
  • Choi K, Chau T, Tsang O, et al. Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong. Ann. Intern. Med. 139, 715–723 (2003).
  • Keeler N, Lingappa J. Severe acute respiratory syndrome: public health response and clinical practice update for an emerging disease. Curr. Opin. Pediatr. 16, 61–69 (2004).
  • Zou Z, Yang Y, Chen J, et al Prognostic factors for severe acute respiratory syndrome: a clinical analysis of 165 cases. Clin. Infect. Dis. 38, 483–489 (2004).
  • Therefore L, Lau A, Yam L, et al. Development of a standard treatment protocol for severe acute respiratory syndrome. Lancet 361, 1615–1617 (2003).
  • Olsen S, Chang H-L, Cheung T, et al. Transmission of the severe acute respiratory syndrome on aircraft. N Engl J. Med. 349, 2416–2422 (2003).
  • Guan Y, Zheng B, He Y, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 302, 276–278 (2003).
  • Webster R. Wet markets — a continuing source of severe acute respiratory syndrome and influenza? Lancet 363, 234–236 (2004).
  • Lin M, Tseng H-K, Trejaut J, et al Association of HLA class 1 with severe acute respiratory syndrome. BMC Meal Genet. 4, 9–15 (2003).
  • Chan P, Ip M, Ng K, et al. Severe acute respiratory syndrome-associated coronavirus infection. Emerg Infect. Dis. 9, 1453–1454 (2003).
  • Chan P, To K-F, Wu A, et al Human metapneumovirus-associated atypical pneumonia and SARS. Emerg. Infect. Dis. 10, 497–500 (2004).
  • Martina B, Haagmans B, Kuiken T, et al. SARS virus infection of cats and ferrets. Nature 425, 915 (2003).
  • Higgins P, Barrow G, Tyrrell D, Snell N, Jones K, Jolley WA study of the efficacy of the immunomodulatory compound 7-thia-8-oxoguanosine in coronavirus 229E infections in human volunteers. Antiviral Chem. Chemother. 2, 61–63 (1991).
  • Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr H. Treatment of SARS with human interferons. Lancet 362, 293–294 (2003).
  • Tan E, Ooi E, Lin C-Y, et al Inhibition of SARS coronavirus infection with clinically approved antiviral drugs. Emerg Infect. Dis. 10, 581–586 (2004).
  • Haagmans B, Kuiken T, Martina B, et al. Pegylated interferon-a protects Type 1 pneumocytes against SARS coronavirus infection in macaques. Nature Med. 10, 290–293 (2004).
  • Loutfy M, Blatt L, Ward S, et al Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome. J. Am. Med. Ass. 290, 3222–3228 (2003).
  • Chu C, Cheng V, Hung I, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 59, 252–256 (2004).
  • Anand K, Ziebuhr J, Wadhwani P, Mesters J, Hilgenfeld R Coronavirus main proteinase (3 CLIm.°) structure: basis for design of anti-SARS drugs. Science 300, 1763–1767 (2003).
  • Chou K-C, Wei D-Q, ZhongW-Z. Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS. Biochem. Biophys. Res. Comm. 308, 148–151 (2003).
  • Li W, Moore M, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronayirus. Nature 426, 450–454 (2003)
  • Marshall E, Enserink M. Caution urged on SARS vaccines. Science 303, 944–946 (2004).
  • Gao W, Tamin A, Soloff A, et al. Effects of a SARS-associated coronayirus vaccine in monkeys. Lancet 362, 1895–1896 (2003).
  • Yang Z-Y, Kong W-P, Huang Y, et al. A DNA vaccine induces SARS coronayirus neutralization and protective immunity in mice. Nature 428, 561–564 (2004).
  • Parry J. WHO confirms SARS in Chinese journalist. Br. Med. J. 328, 65 (2004).
  • Enserink M. Nipah virus (or a cousin) strikes again. Science 303, 1121 (2004).
  • Editorial. Scare Tactics. New Sci. 181(2436), 3 (2004).
  • Madjid M, Lillibridge S, Mirhaji P, Casscells W. Influenza as a bioweapon. J. R. Soc. Med. 96, 345–346 (2003).
  • MacKenzie D. Bird flu's ticking time bomb. New Sci. 181(2440), 6–7 (2004).
  • Pennington H. Politics, media and microbiologists. Nature Rev. Microbial 2, 259–262 (2004).
  • •Interesting view of the political and press aspects affecting the measures taken to deal with novel epidemic pathogens.
  • Muller M, McGeer A, Straus S, Hawryluck L, Gold W Clinical trials and novel pathogens: lessons learned form SARS. Emerg Infect. Dis. 10, 389–394 (2004).
  • Nelson R. Antibiotic pipeline runs dry. Lancet 362, 1726–1727 (2003).
  • Snell N. New treatments for viral respiratory tract infections — opportunities and problems. J. Antimicrob. Chemother. 47, 251–259 (2001).
  • Fidler D. Germs, governance and global public health in the wake of SARS. j Clin. Invest. 113, 799–804 (2004).
  • Snell N. Ribavirin — current status of a broad spectrum antiviral agent. E. Opin.Pharmacother. 2, 1317–1324 (2001).

Website

  • WHO. Severe acute respiratory syndrome (SARS): report by the secretariat. EB 113/33 (2003) www.who.int/csr/sars/country Accessed May 2004
  • •Succinctly summarizes the course of the 2003 SARS epidemic.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.